| Literature DB >> 30863659 |
Dyness Kejo1,2, Pammla Petrucka3,4, Haikael Martin1, Theobald C E Mosha5, Martin E Kimanya1.
Abstract
In Tanzania's Arusha District, anaemia is a significant public health problem. Recently, home fortification with multiple micronutrient powder was recommended, and daily use of one sachet has shown to be effective. However, it is a challenge for deprived families with low income to afford the daily sachet. The aim of this study was to compare the efficacy of different administration frequencies of micronutrient powder in reducing anaemia in children aged 6-59 months. This research used a community-based, randomized longitudinal trial design with the intent to treat anaemia. Children aged 6 to 59 months (n=369) were randomly assigned to one of four intervention groups which received, on a weekly basis, either five sachets (n=60), three sachets (n=80), two sachets (n=105), or one sachet (n=124) for six months; 310 children completed the study. Using the HemoCue technique, a finger-prick blood was taken at baseline, middle, and end points of the intervention to determine haemoglobin levels. The effect of treatment on haemoglobin was assessed with analysis of covariates with Bonferroni post hoc to test group difference (p > 0.05) from each other. At the end, haemoglobin levels were significantly higher in participants who received three or five sachets of micronutrient powder per week compared to those who received one or two micronutrient powder sachets per week (p < 0.05). The prevalence of illnesses was reduced from 65% to 30.5% in all groups. This finding indicates that economically challenged families may opt for three times per week sachet administration rather than a more costly daily administration. This trial is registered with PACTR201607001693286.Entities:
Year: 2019 PMID: 30863659 PMCID: PMC6378028 DOI: 10.1155/2019/8979456
Source DB: PubMed Journal: Scientifica (Cairo) ISSN: 2090-908X
Figure 1Flow diagram of subject's progress through the study.
Baseline characteristics of the study population.
| Characteristics | Treatment group | ||||
|---|---|---|---|---|---|
| 5/wk ( | 3/wk ( | 2/wk ( | 1/wk ( |
| |
| Child age (months) | 17.7 ± 7.9 | 18.5 ± 6.9 | 20.1 ± 10.1 | 14.4 ± 7.9 | <0.001 |
| Birth weight (kg) | 3.1 ± 0.5 (32) | 3.4 ± 0.5 (43) | 4.2 ± 11.5 (70) | 2.9 ± 0.5 (66) | 0.6 |
| Mother's age (years) | 25.3 ± 4.3 | 25.7 ± 4.4 | 25.8 ± 5.4 | 25.9 ± 4.7 | 0.1 |
| Sex, male (%) | 44.7 | 64.3 | 64.2 | 54.1 | 0.08 |
| EBF (%) | 14.9 | 12.9 | 20.1 | 9.2 | 0.1 |
| Stunting (%) | 53.2 | 44.3 | 50.5 | 46.9 | 0.8 |
| Underweight (%) | 21.4 | 24.3 | 27.4 | 21.4 | 0.8 |
| Wasting (%) | 14.9 | 12.9 | 16.8 | 9.2 | 0.1 |
| Marital status, married (%) | 87.2 | 90.0 | 91.6 | 92.9 | 0.7 |
Values are means ± SD; significant at the 0.05 level.
Change in haemoglobin concentrations (mean ± SD) during intervention.
| Duration | Treatment groups | ||||
|---|---|---|---|---|---|
| 5/wk | 3/wk | 2/wk | 1/wk |
| |
| Baseline | 9.0 ± 0.70 | 9.2 ± 0.78 | 9.0 ± 0.79 | 9.0 ± 0.67 | 0.5 |
| Midline | 10.02 ± 0.60 | 9.8 ± 0.78 | 9.6 ± 0.90 | 9.3 ± 0.71 | 0.00 |
| End line | 11.32 ± 0.52 | 11.10 ± 0.8 | 10.80 ± 1.02 | 9.60 ± 0.70 | 0.00 |
Based on ANOVA (continuous variable).
Mean difference of haemoglobin concentration between intervention groups.
| Duration | Comparison group | Mean difference (a − b) ± SE |
| 95% CI | |
|---|---|---|---|---|---|
| (Dose (a)) | (Dose (b)) | ||||
| Midline | 1/wk | 2/wk | −0.45 ± 0.12 | 0.001 | −0.76–−0.15 |
| 3/wk | −0.56 ± 0.12 | 0.00 | −0.89–0.24 | ||
| 5/wk | −0.77 ± 0.14 | 0.00 | −1.14–0.41 | ||
| 2/wk | 1/wk | 0.45 ± 0.12 | 0.00 | 0.47–0.76 | |
| 3/wk | −0.11 ± 0.12 | 1.00 | −0.43–0.21 | ||
| 5/wk | −0.21 ± 0.14 | 0.01 | −0.68–0.04 | ||
| 3/wk | 1/wk | 0.56 ± 0.12 | 0.00 | 0.24–0.88 | |
| 2/wk | 0.11 ± 0.12 | 1.00 | −0.21–0.43 | ||
| 5/wk | −0.21 ± 0.15 | 0.88 | −0.60–0.18 | ||
| 5/wk | 1/wk | 0.77 ± 0.14 | 0.00 | 0.41–1.14 | |
| 2/wk | 0.320 ± 0.14 | 1.00 | −0.05–0.69 | ||
| 3/wk | 0.212 ± 0.15 | 0.88 | −0.18–6.00 | ||
|
| |||||
| End line | 1/wk | 2/wk | −1.21 ± 0.12 | 0.00 | −1.54–0.88 |
| 3/wk | −1.51 ± 0.13 | 0.00 | −1.85–−1.16 | ||
| 5/wk | −1.69 ± 0.15 | 0.00 | −2.09–−1.31 | ||
| 2/wk | 1/wk | 1.21 ± 0.12 | 0.00 | 0.88–1.54 | |
| 3/wk | −0.29 ± 0.29 | 0.13 | −0.64–0.05 | ||
| 5/wk | −0.49 ± 0.15 | 0.006 | −0.88–−0.99 | ||
| 3/wk | 1/wk | 1.51 ± 0.13 | 0.00 | 1.16–1.85 | |
| 2/wk | 0.29 ± 0.13 | 0.13 | −0.05–0.64 | ||
| 5/wk | −0.19 ± 0.15 | 1.00 | −0.60–0.22 | ||
| 5/wk | 1/wk | 1.69 ± 0.15 | 0.00 | 1.31–2.09 | |
| 2/wk | 0.49 ± 0.15 | 0.00 | 0.09–0.88 | ||
| 3/wk | 0.19 ± 0.15 | 1.00 | −0.22–0.6 | ||
The mean difference is significant at 0.05 levels. bAdjusted for multiple comparisons: Bonferroni
The effect of micronutrient powders supplementation on prevalence of anaemia.
| Variable | Treatment groups | ||||
|---|---|---|---|---|---|
| 1/wk | 2/wk | 3/wk | 5/wk | Total | |
| Normal | 0 | 51.6 | 67.1 | 78.7 | 42.9 |
| Mild | 38.8 | 28.4 | 24.3 | 19.1 | 29.4 |
| Moderate | 61.2 | 20.0 | 8.6 | 2.1 | 27.7 |
Impact of supplementation on morbidity.
| Morbidity | No. of respondents | % |
|---|---|---|
| Illness at baseline | 200 | 65.0 |
| Illness after intervention | 95 | 30.6 |